APGE

AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?

06/22 06:36 pm

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)

06/22 01:47 pm

Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors

03/26 11:33 am

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

03/24 09:53 pm

Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026

03/22 07:51 pm

Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million

02/25 04:06 pm

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

01/06 07:00 am

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

11/10 08:00 am

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million

10/10 04:01 pm

Why Apogee Therapeutics Stock Triumphed on Thursday

10/09 05:26 pm

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

10/08 09:52 pm

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

07/07 06:00 am

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

07/06 06:00 pm

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

05/12 06:00 am

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

05/01 08:00 am

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

03/03 07:00 am

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

02/03 08:00 am

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

12/02 07:00 am

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

10/16 07:00 am

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

08/19 07:00 am

Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) By GuruFocus - Investing.com Canada

07/06 12:19 am

Apogee Therapeutics CEO sells shares worth over $558k By Investing.com - Investing.com Australia

07/05 10:57 pm

Apogee Therapeutics CMO sells over $225k in company stock By Investing.com - Investing.com Australia

07/05 10:56 pm

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

05/28 07:30 am

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

05/23 07:30 am

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

05/15 04:01 pm

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

05/13 07:00 am

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference

05/06 08:00 am

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why

03/28 11:01 am

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

03/25 07:00 am

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

03/14 08:57 am

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million

03/12 04:01 pm

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

03/07 07:49 pm

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

03/05 05:23 pm

Crude Oil Down 1%; Dave Shares Jump After Q4 Results

03/05 03:11 pm

Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

03/05 02:11 pm

Nasdaq Down 250 Points; ISM Services PMI Falls In February

03/05 01:05 pm

NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday

03/05 11:56 am

Dow Dips Over 100 Points; Target Posts Upbeat Earnings

03/05 11:01 am

Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

03/05 07:10 am

Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days

03/05 07:00 am

Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024

03/04 05:01 pm

IPO Watch 2024: Which New Stocks Will Hit the Market?

01/09 01:56 pm

Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

01/02 08:30 am

Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky

12/28 08:46 am

Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

12/22 02:28 pm

Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results

11/13 08:30 am

Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress

09/27 08:42 am

Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day

09/14 07:30 am

Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results

08/28 07:30 am